India logs 22,272 new coronavirus cases, 251 deaths ANI | Updated: Dec 26, 2020 11:52 IST
New Delhi [India], December 26 (ANI): With 22,272 new COVID-19 cases recorded in the last 24 hours, India s infections tally has reached 1,01,69,118, informed the Union Ministry of Health and Family Welfare on Saturday.
The country witnessed 251 new COVID-19 deaths during the same period, taking the cumulative toll to 1,47,343. At present, there are 2,81,667 active cases, while the overall recoveries have reached 97,40,108 as 22,274 people were discharged in the last 24 hours.
As many as 16,71,59,289 samples were tested up to December 25, including 8,53,527 samples tested on Friday, according to the Indian Council of Medical Research (ICMR).
Meanwhile, Bharat Biotech Chairman and Managing Director Dr Krishna Ella and Joint Managing Director Suchitra Ella had called on Vice President M Venkaiah Naidu in Hyderabad to discuss the status of the indigenou
Updated Dec 24, 2020 | 11:03 IST
On the distribution of vaccines in India, he said India is well prepared for that and Indian immunisation system is very robust, Ella said. People who have been infected with COVID-19 should also take vaccine, says Bharat Biotech Chairman | Photo Credit: iStock Images
New Delhi: People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech, Chairman & MD Krishna Ella said on Wednesday.
He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post-vaccination era organised by industry body CII.
URL copied
Representational image
People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech Chairman and MD Krishna Ella said on Wednesday. Bharat Biotech is developing Indian own vaccine for coronavirus called Covaxin. He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post vaccination era organised by industry body CII.
For the people who are infected, should they take a vaccine, the answer is yes , because they may not have a good T cells response., Ella said.
Talking about the company s efficacy trials of its COVID-19 vaccine, he said that for the efficacy trials the company has taken 24 centres all over the country so that it has tier I ,tier II and tier III cities to capture the efficacy in a better way.
People who are infected should also take a vaccine,and India is well prepared regarding the logistics for the vaccine distribution,Bharat BiotechChairman & MD Krishna Ella said on Wednesday. He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post vaccination era organised by industrybody CII. For the peoplewho are infected,shouldthey take a vaccine, the answeris yes , becausethey may not have a goodT cells response., Ella said. Talking about the company s efficacy trials of its COVID-19 vaccine, he said that for the efficacy trials the company has taken 24 centres all over the country so that it has tier I ,tierIIand tier III cities to capture the efficacy in a better way.
Who should take coronavirus vaccine? Bharat Biotech s Chairman answers
India
Published: Wednesday, December 23, 2020, 20:50 [IST]
New Delhi, Dec 23: People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech Chairman and MD Krishna Ella said on Wednesday.
Representational Image
Bharat Biotech is developing Indian own vaccine for coronavirus called Covaxin. He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post vaccination era organised by industry body CII.
For the people who are infected, should they take a vaccine, the answer is yes , because they may not have a good T cells response., Ella said.